19
Participants
Start Date
January 17, 2022
Primary Completion Date
January 27, 2025
Study Completion Date
April 30, 2026
Oral Azacitidine
Specified dose on specified days
Placebo
Specified dose of specified days
Local Institution - 0011, Huntsville
Local Institution - 0032, Bunkyo Ku
Local Institution - 0029, Sumida Ku
Local Institution - 0030, Shinjuku-ku
Local Institution - 0006, Sagamihara-shi
Local Institution - 0012, Isehara
Local Institution - 0003, Kashiwa-shi
Local Institution - 0005, Kamogawa
Local Institution - 0001, Maebashi
Local Institution - 0023, Nagoya
Local Institution - 0026, Osaka
Local Institution - 0021, Ōsaka-sayama
Local Institution - 0025, Okayama
Local Institution - 0010, Matsuyama
Local Institution - 0027, Fukuoka
Local Institution - 0008, Nagasaki
Local Institution - 0020, Yoshida Gun
Local Institution - 0019, Kanazawa
Local Institution - 0015, Sendai
Local Institution - 0017, Nagoya
Local Institution - 0009, Toyoake
Local Institution - 0022, Aomori
Local Institution - 0016, Fukuoka
Local Institution - 0014, Ōgaki
Local Institution - 0004, Sapporo
Local Institution - 0013, Yokohama
Local Institution - 0031, Shimotsuke
Local Institution - 0002, Shinagawa
Local Institution - 0018, Fukuoka
Local Institution - 0028, Saitama
Local Institution - 0007, Yamagata
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY